Business Context and Reporting Period
Company: Kura Oncology, Inc. (KURA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Kura is a biopharmaceutical company focused on precision medicines for cancer. In November 2025, the company achieved a pivotal milestone with the FDA approval of KOMZIFTI (ziftomenib), a menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). Commercial sales in the U.S. commenced on November 21, 2025. The company operates under a strategic collaboration with Kyowa Kirin for global development and commercialization outside the U.S., and co-promotion in the U.S.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $67,482 | $53,883 | +$13,599 |
| - Product Revenue (Net) | $2,132 | $0 | +$2,132 |
| - Collaboration Revenue | $65,350 | $53,883 | +$11,467 |
| Operating Expenses | $371,113 | $247,078 | +$124,035 |
| - R&D Expenses | $251,074 | $169,967 | +$81,107 |
| - SG&A Expenses | $119,982 | $77,111 | +$42,871 |
| Net Loss | $(278,666) | $(173,983) | $(104,683) |
| Cash & Equivalents (Dec 31, 2025) | $149,099 | $224,462 | -$75,363 |
| Total Cash, Cash Equivalents & Short-Term Investments | $667,240 | $727,395 | -$60,155 |
| Long-Term Debt (Principal) | $10,000 | $10,000 | $0 |
Note: The filing text does not provide a specific "Gross Margin" percentage due to the immateriality of product sales volume relative to total revenue, though Cost of Product Sales was $57,000.
Material Changes vs. Prior Period
- Revenue Composition: The company transitioned from a pure R&D model to a commercial-stage organization. For the first time, it recognized $2.1 million in net product revenue from KOMZIFTI sales following FDA approval in November 2025. Collaboration revenue increased by 21% to $65.4 million, driven by the Kyowa License Agreement.
- Expense Growth: Operating expenses increased by 50% year-over-year. R&D expenses rose by $81.1 million, primarily due to increased costs for ziftomenib combination trials (including registration-directed frontline trials) and darlifarnib Phase 1 trials. SG&A expenses increased by $42.9 million due to personnel costs and sales/marketing build-out for the KOMZIFTI launch.
- Liquidity Position: Net cash used in operating activities was $64.1 million in 2025, compared to net cash provided by operating activities of $134.3 million in 2024. This shift reflects the timing of revenue recognition under the Kyowa agreement and increased operational burn. However, the company maintains a strong liquidity position with $667.2 million in cash, cash equivalents, and short-term investments.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Commercialization: KOMZIFTI was added to the NCCN Guidelines as a Category 2A recommended treatment. Market access has been rapid, with at least 80% of private payors establishing coverage policies within 90 days of approval.
- Clinical Pipeline: The company is advancing Phase 3 trials (KOMET-017) for ziftomenib in combination with intensive and non-intensive chemotherapy for newly diagnosed AML. Topline results for the accelerated endpoint in the intensive chemotherapy setting are anticipated in 2028.
- Capital Resources: Management believes current cash and investments, combined with anticipated milestone payments of $180 million from Kyowa Kirin between 2027 and 2028, will fund operations into the fourth quarter of 2027 and support the ziftomenib AML program through the 2028 topline results.
Risks and Contingencies
- Commercial Execution: Success is highly dependent on the successful commercialization of KOMZIFTI. The company has limited experience as a commercial entity, and market acceptance by physicians and payors is not guaranteed.
- Regulatory Dependence: Future revenue growth relies on expanding indications for ziftomenib (e.g., frontline AML, GIST) and obtaining regulatory approvals for other candidates like darlifarnib. Failure to maintain FDA approval or obtain new approvals would severely impact the business.
- Collaboration Risk: The company relies on Kyowa Kirin for global commercialization outside the U.S. and co-promotion in the U.S. Termination of the Kyowa License Agreement or failure to meet milestones could result in the loss of significant future revenue streams.
- Profitability: The company has incurred losses since inception and expects to continue incurring significant operating losses for the foreseeable future. It may never achieve or maintain profitability.
Key Facts for Investor Verification
- KOMZIFTI Launch Status: Verify the actual sales uptake and market share of KOMZIFTI in the first full quarter of commercialization (Q1 2026) against the initial $350M-$400M annual market opportunity estimate.
- Kyowa Kirin Milestones: Monitor the achievement of the $180 million in milestone payments expected between 2027 and 2028, which are critical to the company's liquidity runway.
- Phase 3 Trial Progress: Track enrollment rates and interim data from the KOMET-017 Phase 3 trials (frontline AML), as these are the primary drivers for future valuation and potential label expansion.
- Debt Covenants: Confirm continued compliance with the minimum cash covenant (35% of outstanding loan obligations) under the $10 million term loan facility, which is subject to a market capitalization waiver threshold of $1.25 billion.
- Competitive Landscape: Assess the impact of competing menin inhibitors (e.g., Syndax's revumenib) on KOMZIFTI's pricing power and market penetration.